Search - tctmd.com

Displaying 101 - 120 of 253

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

Should We All Become Bayesians?

Presenter: Stuart J. Pocock, Jan G. P. Tijssen

September 23, 2018

Presentation TCT 2018

Is it Time to Toughen Up the P<0.05?

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Peter Juni

September 23, 2018

Presentation TCT 2018

Garbage in Garbage Out: Risks to Big Data Analysis in Interventional Cardiology

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Otavio Berwanger

September 23, 2018

Presentation TCT 2018

No Role for Observational Studies in Effectiveness Comparisons: The Staged vs. Culprit Only PCI for STEMI Case Study

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Robert W. Yeh

September 23, 2018

Presentation TCT 2018

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Presenter: Peter Juni, Robert W. Yeh, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Presenter: Peter Juni, Robert W. Yeh, David J. Cohen

September 23, 2018

Presentation TCT 2018

Most Frequent Errors I See in the Analysis and Interpretation of Trials

Presenter: Peter Juni, Robert W. Yeh

September 23, 2018

Presentation TCT 2018

How to Make Trials Larger, Simpler and Less Expensive

Presenter: Peter Juni, Robert W. Yeh, Matthew T. Roe

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, William F. Fearon

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Bernard J. Gersh

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

Presenter: Ajay J. Kirtane, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

News Conference News TCT 2018

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

Michael O'Riordan

September 22, 2018

News Features

Sticky Business: Will Taxes on Sugary Sodas Help to Dilute America’s Cardiometabolic Crisis?

Lucy Hicks

August 23, 2018

News Opinion Fellow Talk

Finding Your Niche in Medicine: Not a Straight Path

Ankur Gupta, MD, PhD

August 10, 2018

Advertisement

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Should We All Become Bayesians?

Is it Time to Toughen Up the P<0.05?

Garbage in Garbage Out: Risks to Big Data Analysis in Interventional Cardiology

No Role for Observational Studies in Effectiveness Comparisons: The Staged vs. Culprit Only PCI for STEMI Case Study

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Most Frequent Errors I See in the Analysis and Interpretation of Trials

How to Make Trials Larger, Simpler and Less Expensive

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

Sticky Business: Will Taxes on Sugary Sodas Help to Dilute America’s Cardiometabolic Crisis?

Finding Your Niche in Medicine: Not a Straight Path

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content